Skip to main content Deutsch


Alina Nussbaumer-Pröll
Dipl.-Ing. Dr. Alina Nussbaumer-Pröll, BSc.

Department of Clinical Pharmacology
Position: Research Associate (Postdoc)

ORCID: ORCID 0000-0002-8238-8488



Research group(s)

Research interests

My focus lies on in-vitro pharmacokinetic and pharmacodynamic studies with a Hollow Fiber Infection Model (HFIM) supported by standard practice methods for antibiotic susceptibility testing.

Techniques, methods & infrastructure

  • Hollow Fiber Infection Model
  • Minimal Inhibitory Concentration determinations (broth micro/macro-dilution, agar diffusion assays, E-Test etc.)
  • Time Kill Curves

Selected publications

  1. Nussbaumer-Pröll, A. et al. (2022) ‘Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa’, Frontiers in Pharmacology, 13. Available at:
  2. Nussbaumer-Pröll, A.K. et al. (2022) ‘Comparison of Antimycotic Activity of Originator and Generics of Voriconazole and Anidulafungin against Clinical Isolates of Candida albicans and Candida glabrata’, Journal of Fungi, 8(2), p. 195. Available at:
  3. Nussbaumer-Pröll, A. and Zeitlinger, M. (2020) ‘Use of Supplemented or Human Material to Simulate PD Behavior of Antibiotics at the Target Site In Vitro’, Pharmaceutics, 12(8), p. 773. Available at:
  4. Nussbaumer-Pröll, A.K. et al. (2019) ‘Impact of erythrocytes on bacterial growth and antimicrobial activity of selected antibiotics’, European Journal of Clinical Microbiology & Infectious Diseases, 38(3), pp. 485–495. Available at:
  5. Nussbaumer-Pröll, A.K. et al. (2019) ‘Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections’, Journal of Antimicrobial Chemotherapy, 75(3), pp. 593–599. Available at: